Skip to content

Exploration of new technology of personalized neoantigen peptide vaccine in the adjuvant treatment of refractory colorectal cancer patients with recurrence and metastasis

Exploration of new technology of personalized neoantigen peptide vaccine in the adjuvant treatment of refractory colorectal cancer patients with recurrence and metastasis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035795
Enrollment
Unknown
Registered
2020-08-17
Start date
2020-11-30
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carcinoma of colon and rectum

Interventions

Case series:Neoplastic antigen peptide vaccine

Sponsors

Shanghai Public Health Clinical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Histopathologically confirmed (included in the research center) as advanced colorectal cancer, TNM stage as STAGE IIIb-IV; 2. Aged 18-75 years old; 3. Radiotherapy and chemotherapy were not effective, or chemotherapy was not suitable for or unwilling to radiotherapy, unwilling to other immunotherapy, at least one imaging measurable lesion.Expected survival >=3 months.Total bilirubin =50ml/min.

Exclusion criteria

Exclusion criteria: 1. Patients with HIV infection, hepatitis C virus (HCV) infection, uncontrolled coronary artery disease or asthma, uncontrollable cerebrovascular disease or other diseases that researchers consider not eligible for inclusion.Those with a history of bone marrow or organ transplantation; 2. People with coagulation disorders; 3. Subjects with immunodeficiency disease or autoimmune disease; 4. Patients who have had other immunotherapy within 1 month (such as immunocheckpoint inhibitor therapy, therapeutic antibody therapy, immunocell therapy and immunoregulator therapy); 5. May be allergic to immunotherapy; 6. Drug and alcohol abuse, clinical or psychological or social factors influence informed consent or research implementation; 7. Pregnant and lactating women; 8. Is currently participating in or has participated in other clinical trials within a month; 9. Any uncertainties affecting patient safety or compliance; 10. Survivors of secondary brain metastases.

Design outcomes

Primary

MeasureTime frame
The incidence and severity of adverse events and specific laboratory abnormalities (CTCAE V4.03) in all treated subjects;

Contacts

Public ContactYan Liu

Shanghai Public Health Clinical Center

liuyan@shphc.org.cn+86 18616997883

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026